Sponsor-Investigators

Noah M. Hahn

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status

Cancer Types

Bladder

Locations

Columbia University Irving Medical Center, Fox Chase Cancer Center, Fred & Pamela Buffett Cancer Center, Indiana, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Iowa, Maryland, Missouri, Nebraska, New York, Pennsylvania, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, University of Iowa Holden Comprehensive Cancer Center

GU12-160

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160

Status

Closed

Cancer Types

Bladder

Locations

GU12-157

A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157

Status

Closed

Cancer Types

Bladder

Locations

GU07-122

A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

Status

Closed

Cancer Types

Bladder

Locations